The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

NCT02696135 · tracked via the Priya Life Science China tracker

Sponsor

China National Center for Cardiovascular Diseases

Phase

Observational

Started

2011-03-23

Last updated

2018-03-27

Condition(s) studied

Cardiomyopathy, Hypertrophic

Study summary

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF/AHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Accepted

Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM. Exclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.

Primary outcome measure(s)

Cardiovascular deaths — an average of 2 years
Including SCD and deaths due to heart failure and stroke.

Trial sites (1)

Facility	City	Region	Status
Fuwai hospital	Beijing	Beijing Municipality	Recruiting

More China National Center for Cardiovascular Diseases trials in China

No-Touch Versus Conventional Saphenous Vein Harvesting Technique Active, not recruiting

A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation Starting soon

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI Recruiting

CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study Recruiting

An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death Active, not recruiting

Other trials for the same condition

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02696135 on ClinicalTrials.gov ↗ ← All trials in China